Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimasertib vs Dacarbazine in NRAS-Mutated Melanoma
NCT01693068Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Dec 2012
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of pimasertib in cutaneous melanoma (CM), sponsored by EMD Serono. Started Dec 2012; status: completed.
02
Drugs
pimasertib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT01693068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01693068.